Suanfarma Suanfarma

X

Find the latest Drugs in Development and Pipeline Prospector News of Kalos Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Kalos Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
2550 W Union Hills Dr, Suite 350 Phoenix, AZ 85027
Telephone
Telephone

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

ValiRx had entered into an agreement with Kalos Therapeutics, whereby ValiRx would perform a range of preclinical evaluation experiments to determine whether to enter a full licensing agreement for KTH222.


Lead Product(s): KTH222

Therapeutic Area: Oncology Product Name: KTH222

Highest Development Status: PreclinicalProduct Type: Peptide

Partner/Sponsor/Collaborator: ValiRx

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 27, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, ValiRx has the right to perform a defined series of preclinical, cell-based assays to consider the benefit of using KTH222 in combination with standard of care treatment, Paclitaxel.


Lead Product(s): KTH222

Therapeutic Area: Oncology Product Name: KTH222

Highest Development Status: PreclinicalProduct Type: Peptide

Partner/Sponsor/Collaborator: ValiRx

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 10, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Kalos has identified numerous immune-stimulating agents and will target two based on safety and efficacy, as well as other desirable attributes, to begin development.


Lead Product(s): KTH-222

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In 2019, Kalos Therapeutics signed a Letter of Intent with Oncology Pharma, for a worldwide license and co-development of Kalos's lead anti-cancer drug, KTH-222.


Lead Product(s): KTH-222

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Peptide

Partner/Sponsor/Collaborator: Oncology Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 06, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY